Scrub typhus is also known as bus typhus inaction and it is a serious public health problem in the Asia-Pacific area. It threatens one billion peoples are effected worldwide, and causes illness in one million people for an each year. Caused by Orientia tsutsugamushi, scrub typhus can result in severe multi organ failure with a case fatality rate up to 70% without appropriate treatment. The antigenic heterogeneity of O. Tsutsugamushi precludes generic immunity and to the allows reinjection. As it is a neglected disease, there is still a large gap in our knowledge of the disease, as evidence by the sporadic epidemiologic data and others relating to the public health information regarding scrub typhus in its endemic areas. It is a gram-negative bacterium, this infection can be perfectly treated with the specific antibiotics. Early treatment gives best results those who are infected with this infection it gives better therapeutic outcomes. Oral medication is effective for mild cases, but the parenteral route is often necessary for severely ill patients. Similar to treatment for other rickettsial diseases, doxycycline is one of most effective antibiotics for treating scrub typhus infection.
INTRODUCTION
crub typhus or bus typhus inaction (Orientia tsutsugamushi infection) is transmitted by the bite of larval trombiculid mites and is endemic to the land mass within the triangle bounded by Japan to the north, Northern Australia to the south, and the Arabian Peninsula to the west. Mortality in the pre-antibiotic era was variable and in some series, approached 60%, 1 but specific and effective antimicrobial chemotherapy is now available. Scrub typhus often presents as fever with little to distinguish it clinically from co-endemic diseases such as typhoid, leptospirosis, and dengue. The presence of an eschar supports the diagnosis but is variably present. 2 Diagnosis, therefore, depends on clinical suspicion, prompting the clinician to request an appropriate laboratory investigation, and failure to diagnose the disease will likely result in treatment with ineffective β-lactam-based regimens.
The mainstay in scrub-typhus diagnostics remains serology. The oldest test in current use is the Weil-Felix OX-K agglutination reaction, which is inexpensive, easy to perform, and results are available overnight; however, it lacks specificity and sensitivity. The indirect fluorescent antibody (IFA) test is more sensitive, and results are available in a couple of hours; however, the test is more expensive and requires considerable training. IFA uses fluorescent anti-human antibody to detect specific antibody from patient serum bound to a smear of scrub-typhus antigen and is currently the reference standard.Indirect immunoperoxidase (IIP) eliminates the expense of a fluorescent microscope by substituting peroxidase for fluorescein 3 .
Etiology and Epidemiology
Scrub typhus is a life-threatening infectious disease that presents as an acute undifferentiated febrile illness. Its agent, Orientia tsutsugamushi, is an obligately intracytosolic bacterium that is transmitted by feeding larval trombiculid mites, which are the reservoir of the 4 It seems that chigger cofeeding on rodents is more relevant for effective mouse-to-mite transmission of Orientia than feeding on rickettsemic hosts. 5 Thus, the true role of rodents as reservoirs requires additional investigation, because there may be marked genetic variability in chiggers with respect to the ability to acquire rickettsiae by feeding. Also, rodents may be better considered as dead-end hosts just as humans are rather than a reservoir. However, the evolutionary selection of tremendous antigenic diversity of the immunodominant major 56 kDa surface protein presents an enigma if immune variation plays no role in survival of O. tsutsugamushi. 6 The potential immunomodulatory effects of the saliva of larval mites on the pathogenesis of and immunity to infection with O. tsutsugamushi remain undetermined. One million cases of scrub typhus occur each year with an estimated 10% case fatality rate unless treated appropriately, very likely resulting in more deaths than dengue. 7 Currently, scrub typhus has predominantly been reported from an area extending from the Russian Far East and Korea in the north to northern Australia in the south and Afghanistan in the west, and it includes islands of the western Pacific and Indian Oceans, including Japan, Taiwan, Philippines, Papua New Guinea, Indonesia, and Sri Lanka. 8 This geographical range may be an underrepresentation, because case reports have been published from Africa and South America. The recent isolation of a novel species O. chuto acquired by a patient in Dubai, the detection of another divergent Orientia transmitted to a patient in Chile, and serologic diagnoses of scrub typhus acquired in Africa indicate that a wider geographic distribution and genetic diversity of the genus should be investigated. The burden of disease in rural areas of Asia is large, with studies showing scrub typhus causing up to 20% of febrile hospital admissions, an incidence of infections of greater than 3% of the population monthly, seroprevalence over 50% of the population, despite a significant annual rate of reversion to seronegativity of 50% of cases, and a seroconversion rate of 484 per 1,000 person-years 9 . In 1999, the World Health Organization (WHO) stated, "Scrub typhus is probably one of the most under diagnosed and underreported febrile illnesses requiring hospitalization in the region. This opinion remains valid today and could justifiably be adjusted to scrub typhus is probably the single most prevalent, under-recognized, neglected, and severe but easily treatable disease in the world. This ancient disease is currently undergoing increased awareness both because of re-emergence and rising incidence in previously unrecognized areas and improved diagnostic testing. It is apparent that scrub typhus has been recognized to occur frequently now in places where the illness was nearly forgotten, including India, Sri Lanka, the Maldives, and Micronesia. However, scrub typhus has also emerged in regions north of the Yangtse River in China, where it was not known previously. The emergence of scrub typhus should also take into consideration the expansion of farmlands that have generated ideal habitats for trombiculid mites. The potential relationship with global climate change is unclear. Greater recognition in some countries, such as Thailand, Laos, Taiwan, and Japan, may reflect increased medical investigations and application of new diagnostic methods 9 . The critical unresolved issues regarding epidemiology emphasize the need to determine the reasons for emergence and re-emergence and the true incidence of this neglected disease, for which calculated days of disability-adjusted years of life lost (DALYs) have not been determined and to which appropriate attention has not been paid. The traditional endemic area of scrub typhus is known as the tsutsugamushi triangle. It is a Region covering more than 8 million km2, from the Russian Far East in the north, to Pakistan in the west, Australia in the south, and the Japan in the east . There are one billion people at risk of infection; the endemic area is highly populated. The progress of globalization and associated travel contributes to the exportation of the infected persons to non endemic areas the antigenic and genetic diversity of O. tsutsugamushi strains, and their unclear correlation with virulence for humans, confounds the epidemiological study of scrub typhus 10 . Better understanding of the epidemiology of scrub typhus will help efforts to prevent and control the disease. This part of the article describes studies of the geographic distribution and risk factors of scrub typhus in both the endemic areas and in travellers from the rest of the world.
Clinical Diagnosis
The mainstay in scrub-typhus diagnostics remains serology. The oldest test in current use is the Weil-Felix OX-K agglutination reaction, which is inexpensive, easy to perform, and results are available overnight; however, it lacks specificity and sensitivity 3 The indirect fluorescent antibody (IFA) test is more sensitive, and results are available in a couple of hours; however, the test is more expensive and requires considerable training. IFA uses fluorescent anti-human antibody to detect specific antibody from patient serum bound to a smear of scrub-typhus antigen and is currently the reference tandard.4 Indirect immunoperoxidase (IIP) eliminates the expense of a fluorescent microscope by substituting peroxidise for fluorescein. 3 All currently available serological tests for scrub typhus have limitations in which clinicians need to be aware, despite their widespread use. Although agreement exists that a ≥ 4-fold increase in antibody titer between two consecutive samples is diagnostic, 4 such a diagnosis is retrospective and cannot guide initial treatment. Diagnosis based on a single acute-serum sample requires using a cut-off antibody titer. Cut offs ranging from 1:10 to 1:400 are quoted, often with little corroborating evidence 4 and without establishing titers in the healthy local population (necessary to distinguish background immunity from acute infection); that cut off is then used for all patients, Unfortunately, in a setting where eschars are present in 7% of patients, 2 for example, eschar-based tests can have a maximum sensitivity of only 7%. Using buffy coat could improve sensitivity compared with whole blood, 13 but bloodbased assays are positive only during the time window of rickettsemia. It the optimal PCR target remains unclear; nested primer pairs and the Bst DNA polymerase. There is no complicated DNA extraction procedure, and unlike PCR, the entire reaction takes place at the same temperature. This means that only a water bath or heating block is required, whereas PCR requires a thermocycler. The reaction is read visually (a positive reaction produces a white pellet) and does not require special equipment. 13 A small proof-of-principle study (nine patients) showed that LAMP could detect DNA levels as low as 14 copies/μL compared with 3 copies/ μL for real-time PCR). 13 However, the technique has yet to be validated in a prospective clinical trial. Clinicians will remain dependent on serological methods until these issues are resolved, but work can be done to optimize their performance. Cut offs must be validated locally, and previously undiscovered serotypes must be assiduously searched for by examining rodents and chiggers, not merely BSL3 = bio safety level 3; + = low/poor; +++++ = high/excellent on a five-point qualitative scale. Validated against IFA alone but instead, be compared against a panel of both serological and antigen-detection assays (e.g., IFA with 47-kDA and/or 56-kDa PCR).
Management

Supportive Treatment
Patients with mild disease presenting with fever without organ dysfunction may require only antipyretics along with antibiotics. Patients presenting with organ dysfunction would need organ support depending on the nature and extent of organ dysfunction 10 . Patients with respiratory failure could be supported either by means of non-invasive or invasive mechanical ventilation based on standard criteria in the management of respiratory failure. Those with circulatory shock can be treated with fluid resuscitation and vasoactive therapy if the blood pressure does not improve with fluids. Acute kidney injury, which is not uncommon in scrub typhus, may need renal replacement therapy. Those with DIC with clinical bleeding would require transfusion of blood products depending on the nature of coagulation derangement.
Specific treatment
The drug treatment options in scrub typhus have been evaluated and summarized in a recent meta-analysis. In the 17 studies that were included in the meta-analyses, six antibiotics were used and included doxycycline, chloramphenicol, azithromycin, rifampicin, roxithromycin and tetracycline. Conventionally, the treatment of scrub typhus involves the use of the tetracycline group of antibiotics or chloramphenicol. Since these drugs are contraindicated in pregnancy and in children, alternative agents such as quinolones and macrolides are used for the treatment of scrub typhus in this setting 11 .
In the four studies that compared azithromycin with chloramphenicol, chloramphenicol treatment was associated with significantly shorter median time to clearance of fever and lower adverse events when
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[54] CODEN (USA): AJPRHS compared with azithromycin 12 . Six studies compared doxycycline with chloramphenicol; symptom clearance time was significantly shorter with doxycycline. No significant differences were observed in symptom duration comparing azithromycin with doxycycline (3 studies), roxithromycin with doxycycline (3 studies) and doxycycline with either rifampicin or tetracycline (2 studies each) 13 . Doxycycline is the preferred drug in the treatment of scrub typhus. A therapeutic response to doxycycline therapy is used as a diagnostic test. In less sick patients oral doxycycline can be administered at 100 mg twice daily. The duration of treatment is 7 d. In critically ill patients, particularly those in shock, the absorption of enterally administered doxycycline may be problematic. In such situations, intravenous doxycycline should be used; where unavailable, intravenous azithromycin may be used in isolation or combined with enteral doxycycline. Azithromycin is also the recommended drug for treatment of scrub typhus in pregnancy. Rifampicin may be considered where doxycycline resistance is present. In one trial of patients with mild scrub typhus, Rifampicin was found to have shorter defervescence time when compared with doxycycline. However, in tuberculosis endemic countries, rifampicin should be avoided for the treatment of scrub typhus. Although there is some evidence for the use of quinolones in scrub typhus, recent reports of quinolone resistance suggests that this treatment should not be used in critically ill patients. Preliminary reports suggest that Telithromycin is a promising new antibacterial agent for patients with mild to moderate scrub typhus 14 . The different antimicrobial agents used in scrub typhus
Current Prevention Methods
There is no vaccine available for any rickettsial infections including scrub typhus. The enormous antigenic variation in different O. Tsutsugamushi strains, and weak and short lived cross protection among different strains hamper the development of an effective vaccine. Vaccine efforts are also hindered by the different antigenically divergent strains of O. tsutsugamushi in different endemic countries/regions, or even among different strains in the same location WHO recommends prophylactic treatment under special circumstances in the endemic areas. A single oral dose of doxycycline, chloramphenicol or tetracycline every 5 days for a total of 35 days provided protection against Orientia infection. A prospective randomized double blind study among Taiwanese military personnel confirmed that prophylactic treatment with doxycycline could decrease the incidence of scrub typhus to 1/5 of that in the placebo group 15 . The US army has used a weekly dose of doxycycline to prevent scrub typhus. However, CDC in the U.S. does not recommend using antibiotics as prophylaxis for rickettsial diseases including scrub typhus because the preventive treatment may simply delay onset of disease and make diagnosis more difficult. To treat rickettsial diseases more effectively, CDC suggests starting treatment based on clinical suspicion alone 16 . General protective measures can be followed to avoid the infection. These precautions are critical for people living in or visiting endemic areas 
CONCLUSION
I concluded that the scrub typhus infection can be caused by the Orientia tsutsugamushi, is an obligately intracytosolic bacterium that is transmitted by feeding larval trombiculid mites and it can be treated with the specific antibiotics. Early treatment gives best results those who are infected with this infection it gives better therapeutic outcomes. Oral medication is effective for mild cases, but the parenteral route is often necessary for severely ill patients. Similar to treatment for other rickettsial diseases, doxycycline is one of most effective antibiotics for treating scrub typhus infection.WHO propose or the prophylactic treatment under special circumstances in the endemic areas and it can be used a single oral dose of doxycycline, chloramphenicol or tetracycline every 5 days for a total of 35 days provided protection against Orientia infection.
